Optical coherence tomography technology developer NinePoint Medical has received U.S. Food and Drug Administration (FDA) clearance for the use of its NvisionVLE imaging system in the pancreas and bile duct.
As a result, gastroenterologists can now utilize NvisionVLE to perform high-resolution volumetric imaging of the tissue surface and subsurface during biliary examinations, according to the firm. NinePoint noted that its low-profile optical probe is a 7 French diameter imaging probe designed to handle small and tortuous anatomies such as those found in the pancreaticobiliary system.
NvisionVLE was previously cleared for use in esophageal applications.
